PDCD1 and lung carcinoma: Next, we examined the effect of combining L-ASP treatment and ICB (anti-PD-1/anti-PD-L1 antibodies) in a preclinical model of lung carcinoma (CMT167-bearing mice)29 (Fig. 7g).